Brief: Scopus Biopharma Received Deficiency Letter From Nasdaq
27/05/2022 23:16
May 27 (Reuters) - Scopus Biopharma Inc SCPS.O :
* SCOPUS BIOPHARMA - ON MAY 23, RECEIVED DEFICIENCY LETTER
FROM
NASDAQ INDICATING CO IS NOT IN COMPLIANCE WITH NASDAQ’S MAJORITY
INDEPENDENT REQUIREMENT
Further company coverage: SCPS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scopus Biopharma
See all newsBrief: Scopus Biopharma - Nasdaq Hearings Panel Informed Company, By Letter Dated December 15, Of Its Determination To Delist Co's Common Stock From Nasdaq
Brief: Scopus Biopharma Completes Recapitalization To Enhance Shareholder Value
Brief: Scopus Biopharma Says Received Additional Non-Compliance Letter From Nasdaq
Brief: Scopus Biopharma Received Deficiency Letter From Nasdaq
Brief: Scopus BioPharma Inc- On April 4, Received Deficiency Notification Letter From Nasdaq Indicating Co Was Not In Compliance With Nasdaq Listing Rule